Pure Global AI
NCT06383182Not yet recruiting

Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion

Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion: a Prospective, Registry Study
General Hospital of Shenyang Military RegionClinicalTrials.govprocedure
Verified
Study focus
Disease/Condition
Ischemic Stroke
Drug/Device/Intervention
endovascular treatment
Study type
Observational
Intervention type
procedure
Sponsor & location
Primary sponsor
General Hospital of Shenyang Military Region
Location
ShenYang, China
Timeline & enrollment
Phase
N/A
Start date
May 07, 2024
End date
Dec 30, 2026
Enrollment
200 participants
Primary outcome

Dynamic changes in serum biomarkers after endovascular treatment

Summary

Acute ischaemic stroke (AIS) results in high rates of neurological morbidity and mortality,
 especially in patients with large vessel occlusion (LVO). Endovascular therapy (EVT) has been
 approved as the most effective treatment for patients with LVO , but about half patients
 undergoing EVT did not achieve good outcome. The mechanisms of poor prognosis are complex.
 How to accurately identify serological biomarkers related to patients' clinical prognosis is
 an important research topic nowadays.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedOther cerebral infarction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06383182
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06383182 through Pure Global AI's free database. This phase not specified trial is sponsored by General Hospital of Shenyang Military Region and is currently Not yet recruiting. The study focuses on Ischemic Stroke. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.